TY - JOUR T1 - Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility) JF - Thorax JO - Thorax SP - 176 LP - 179 DO - 10.1136/thoraxjnl-2019-213879 VL - 75 IS - 2 AU - Irene J Higginson AU - Andrew Wilcock AU - Miriam J Johnson AU - Sabrina Bajwah AU - Natasha Lovell AU - Deokhee Yi AU - Simon P Hart AU - Vincent Crosby AU - Heather Poad AU - David Currow AU - Emma Best AU - Sarah Brown A2 - , Y1 - 2020/02/01 UR - http://thorax.bmj.com/content/75/2/176.abstract N2 - New treatments are required for severe breathlessness in advanced disease. We conducted a randomised feasibility trial of mirtazapine over 28 days in adults with a modified medical research council breathlessness scale score ≥3. Sixty-four patients were randomised (409 screened), achieving our primary feasibility endpoint of recruitment. Most patients had COPD or interstitial lung disease; 52 (81%) completed the trial. There were no differences between placebo and mirtazapine in tolerability or safety, and blinding was maintained. Worst breathlessness ratings at day 28 (primary clinical activity endpoint) were, 7.1 (SD 2.3, placebo) and 6.3 (SD 1.8, mirtazapine). A phase III trial of mirtazapine is indicated. Trial registration: ISRCTN 32236160; European Clinical Trials Database (EudraCT no: 2015-004064-11). ER -